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CLEARANCE KINETICS OF A SINGLE INJECTION
CROSSLINKED HYLAN-BASED VISCOSUPPLEMENT IN
A RABBIT MODEL
N.E. Larsen1, H. Dursema1, E.M. Skrabut2
1Genzyme Biosurgery, Ridgeﬁeld, NJ; 2Genzyme, Cambridge,
MA
Purpose: Hyaluronan-based viscosupplements are widely used
for treating pain due to osteoarthritis. The majority of viscosup-
plements require multiple injections in order to achieve sustained
pain relief. A chemically modiﬁed hyaluronan product (hylan G-F
20) intended to provide pain relief with only one injection was
developed. A rabbit model was utilized to evaluate the clearance
of hylan ﬂuid and hylan gel components of the single injection
hylan G-F 20 product following intra-articular injection.
Methods: Radioactive hylan ﬂuid was prepared by incorporating
14C-acetic acid into the culture medium of chicken comb organ
cultures. Radiolabeled hylan A was extracted from the combs and
puriﬁed. Thec14C-hylan A was diluted with non-labeled hylan ﬂuid
to a speciﬁc activity of 1.61x105 DPM/mg. Radiolabeled hylan
gel was prepared by using tritiated water during the process of
chemically crosslinking the hylan with divinyl sulfone (DVS). The
tritium was incorporated into the sulfonyl-bis-ethyl crosslink and
also into hydroxyethyl-sulfonyl-ethyl pendant groups. The result-
ing 3H-hylan gel had a speciﬁc activity of 3.72x105 DPM/mg.
The ﬂuid and gel were mixed in a 80:20 ratio (v/v), resulting in
hylan G-F 20 and then ﬁlled into syringes. Twelve New Zealand
White rabbits weighing between 2.5 and 3.5 kg were used in this
IACUC approved study. Rabbits were assigned to one of four
groups, of three rabbits each, and anesthetized prior to injection.
Radiolabeled hylan G-F 20 was administered by intra-articular
injection at a volume of 0.3 ml (6 ml/60 kg body weight) per joint.
One group of rabbits was sacriﬁced at each of the folowing time-
points: 1 day, 3 days, 1 week and 4 weeks following injection.
At each timepoint, synovial ﬂuid, joint tissues, blood, popliteal
lymph nodes, liver, spleen, kidney, and lung were collected and
analyzed for radioactivity by dual channel scintillation counting.
Results: The clearance of 14C-hylan ﬂuid was found to follow ﬁrst
order decay kinetics with an apparent half-life of 1.5±0.2 days.
Clearance of 3H-hylan gel was also found to follow ﬁrst order
decay kinetics, but with an apparent half-life of 8.8±0.9 days. All
of the measurable radioactivity was found within the joint. There
was no radioactivity detected in the blood or the major internal
organs.
Conclusions: The ﬂuid and gel components from a single injec-
tion hylan G-F 20 were cleared from the joint without detectable
accumulation in the blood or internal organs. With the prolonged
half-life of hylan gel, hylan is still available within the joint at times
in excess of three weeks post intra-articular injection. However,
greater than 95% of the total hylan is cleared from the joint by 4
weeks.
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DIFFERENT EFFECTS OF HIGH MOLECULAR WEIGHT
SODIUM HYALURONATE AND NSAID ON THE
PROGRESSION OF THE CARTILAGE DEGENERATION IN
RABBIT OSTEOARTHRITIS MODEL
M. Mihara, N. Koike, Y. Uchiyama
Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Purpose: To examine the inﬂuence of nonsteroidal anti-
inﬂammatory drug (NSAID) and intra-articular injections of high
molecular weight sodium hyaluronate (HA) on pain and cartilage
degeneration in rabbit osteoarthritis model induced by partial
meniscectomy.
Methods: Loxoprofen sodium, which is the most popular NSAID
in Japan was administered p.o. daily for 14 days at a dose of
4 mg/kg, starting from the day of meniscectomy. Suvenyl® used
as a high molecular weight HA, was injected intra-articularly into
injured knee every 3 days from the day of surgery. There was
4 groups: control group (water p.o.+saline i.a.), NSAID group
(NSAID p.o.+saline i.a.), HA group (water p.o.+HA i.a.) and
NSAID+HA group (NSAID p.o.+HA i.a.). The effect on pain was
assessed by weight bearing on hind paw using an Incapacitance
Tester, and the damage of cartilage was evaluated by visual
assessment and histopathology at 14 days after the surgery.
Results: Hind paw weight bearing on injured paw decreased
time-dependently in the control group. In NSAID group, HA group
and NSAID+HA group, the decrease of weight bearing on injured
paw was not observed through the experiment, demonstrating
an analgesic effect. Visible damage and histopathological ﬁnd-
ings of cartilage degeneration were evident in the cartilages
of the control group. In the HA group, the damaged cartilage
area decreased and cartilage degeneration was ameliorated. In
contrast, in NSAID group, the cartilage degeneration was aug-
mented compared with the control group. And, this exacerbated
cartilage degeneration induced by NSAID was reversed by the
concomitant use of HA.
Conclusions: Taken together with the fact that the onset of
analgetic effect of NSIAD is more rapid than that of HA, the
treatment with high molecular weight HA from earlier stage




ELEVATED URINARY CTX-II LEVELS PREDICT OA
PROGRESSION AND CARTILAGE LOSS OVER 21
MONTHS
E.B. Dam, C. Christiansen, M.A. Karsdal
Nordic Bioscience, Herlev, Denmark
Purpose: The progression of osteoarthritis (OA) is characterized
by increased bone and cartilage metabolism already during the
early stages of OA. The biochemical marker uCTX-II quantiﬁes
collagen type II fragments in the urine as the result of cartilage
breakdown. In this study we investigated whether the level of
uCTX-II could predict progression of knee OA as deﬁned by
radiographic signs and whether it could predict cartilage loss.
The ability to predict OA progression and cartilage loss is central
for prognostics markers to be used in selection criteria in clinical
studies of potential disease modifying OA drugs (DMOADs).
Methods:A randomized population of 159 subjects was prospec-
tively selected with age 21 to 81 years (mean 56), BMI 19 to
38 (mean 26), and 48% female. Radiographs were acquired
in a load-bearing semi-ﬂexed position using the SynaFlex. MRI
scans with near-isotropic voxels were acquired from a Turbo 3D
T1 sequence from a 0.18T Esaote scanner (40° FA, TR 50 ms,
TE 16 ms, scan time 10 minutes, resolution 0.7 x 0.7 x 0.8mm3).
Fasting morning urine samples (second void) were collected.
Radiographs and MR scans of left and right knees were acquired
at baseline (BL), after one week for a subgroup of 31 knees, and
at follow-up (FU) after 21 months. 25 knees were used for training
of the computer-based quantiﬁcation method and excluded from
the study that had 288 knees at BL and 245 knees at FU. Urine
sample were acquired at BL. The Kellgren and Lawrence (KL)
score was evaluated for each knee from the radiographs at BL
and FU in the medial tibio-femoral compartment and cartilage
volume was quantiﬁed by a fully automatic, computer-based
framework in the medial tibial and femoral compartments. The
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urinary levels of collagen type II C-telopeptide fragments (uCTX-
II) were measured by the CartiLaps ELISA assay. uCTX-II was
corrected by urinary creatinine levels as assessed by a standard
colorimetric method. In order to achieve approximately normal
distribution, log(uCTX-II) was used as the marker.
At BL, the distribution of KL scores was (145,88,30,24,1) for
KL 0-4. Among the BL healthy knees (KL 0), 101 were non-
progressors at FU and 25 were progressors (KL > 0) at FU.
Results: The mean total cartilage volume at BL was quantiﬁed
to 6851 mm3 with scan-rescan CV of 3.6% (the intra-scan CV
is zero since the method is fully automatic). The uCTX-II at
BL was higher for the progressors than for the non-progressors
(244 vs 173 ng/mmol, p<0.01, sample size 67, odds ratio 6.2,
Figure 1). The cartilage loss for the low uCTX-II group (less than
mean uCTX-II) at BL was lower than for the high uCTX-II group
(p=0.02, Figure 2).
Figure 1. Increased uCTX-II at BL was a predictor of early OA progression as
deﬁned by radiographic signs (increased KL score at FU from 0 at BL).
Figure 2. Increased uCTX-II at BL was a predictor of cartilage loss over 21
months.
Conclusions: Clinical trials of potential DMOADS rely on proper
selection of the study population. The selection criteria must
ensure that the population is likely to progress in OA level without
treatment - otherwise it will be impossible to show a treatment
effect for any DMOAD. The results suggested that uCTX-II is
indeed a suitable prognostic marker for use in selection criteria.
Elevated BL uCTX-II implies an increased risk of OA progression
(progressors are 41% increased, odds ratio 6.2) - deﬁned by
either KL score or by cartilage loss. Thereby, the pair of uCTX-II
and cartilage volume biomarkers seems suitable for selecting
the study population and for quantifying the treatment efﬁcacy in
clinical studies.
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SYNCHROTRON FTIR ANALYSIS OF ARTICULAR
CALCIUM-CONTAININGCRYSTALS
E. Mattson1, C. Hirschmugl1, C.M. Gohr2, A.K. Rosenthal2
1University of Wisconsin Milwaukee, Milwaukee, WI; 2Medical
College of Wisconsin, Milwaukee, WI
Purpose: Sixty percent of synovial ﬂuids from patients with
severe osteoarthritis contain calcium pyrophosphate dihydrate
(CPPD) or basic calcium phosphate (BCP) crystals. Problems
in accurately identifying and characterizing calcium-containing
crystals have slowed progress towards understanding the role
of these pathologic crystals in osteoarthritis. Synchrotron FTIR
(sFTIR) analysis has been useful to study mineral formation in
bone. We sought to determine if it could be used in human
synovial ﬂuid and in mineralization models to identify and char-
acterize calcium-containing crystals
Methods: Discarded synovial ﬂuids containing native CPPD or
BCP crystals were obtained in accordance with our local IRB.
Biosynthetic calcium-containing crystals were generated in vitro
using well characterized models of crystal formation, including
a cell culture model with porcine articular chondrocytes and a
model utilizing isolated porcine articular cartilage vesicles. Truly
synthetic CPPD and BCP crystals were generated in our lab-
oratory in an inorganic milieu. Crystal containing material was
placed on an IR reﬂective slide. Crystal-containing areas were
identiﬁed with light microscopy, and examined with a Thermo
Fisher Continuum FTIR Microscope at the Synchrotron Radia-
tion Center in Stoughton, WI. The FTIR spectra generated were
compared with known spectra of multiple forms of pure calcium
phosphate and calcium pyrophosphate crystals, as well as spec-
tra generated with truly synthetic CPPD and BCP crystals and
cartilage proteoglycans alone and in mixtures.
Results: sFTIR readily identiﬁed both CPPD and BCP crystals
in synovial ﬂuids and in articular cartilage vesicle models. Most
CPPD crystals were monoclinic. CPPD crystals identical to those
seen in synovial ﬂuids were also readily identiﬁable in articular
chondrocyte monolayers incubated with ATP. Most of the BCP
crystals from synovial ﬂuids and models were consistent with
hydroxyapatite, rather than with the other calcium phosphate
crystals types known to be present in BCP. Interestingly, careful
examination of different regions of human or porcine material
often revealed both CPPD and BCP containing areas in a single
crystal aggregate. In spectra from many CPPD crystals, the peak
at the 1134 cm -1 frequency region found on the standard spec-
trum for CPPD was absent or diminished. Addition of cartilage
proteoglycans to truly synthetic CPPD crystals dampened the
peak at this frequency region, much as this peak was diminished
in biosynthetic or native CPPD.
Conclusions: sFTIR analysis allows for accurate identiﬁcation of
CPPD and BCP crystals generated in vivo or in vitro. These data
support the presence of mixtures of crystals in a single region,
and prove the validity of the monolayer model of CPPD crystal
formation. they demonstrate crystal-proteoglycan interaction in
vivo and in vitro. This novel application of sFTIR should further
our understanding of the role of these crystals in osteoarthritis.
